Skip to main content
. 2024 Nov 19;24:3214. doi: 10.1186/s12889-024-20716-1

Table 2.

Risk of CVD associated with Decline in Percentage of Predicted FEV1

Outcomes N Events Model 1 Model 2 Model 3
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
CHD
 Nonrapid decliners 22246 826 Ref Ref Ref
 Rapid decliners 7416 310 1.129 (0.991–1.287) 0.068 1.159 (1.016–1.320) 0.028 1.150 (1.009–1.311) 0.036
Arrhythmia
 Nonrapid decliners 22246 1007 Ref Ref Ref
 Rapid decliners 7416 421 1.262 (1.127–1.414) < 0.001 1.308 (1.167–1.466) < 0.001 1.307 (1.167–1.465) < 0.001
HF
 Nonrapid decliners 22246 184 Ref Ref Ref
 Rapid decliners 7416 83 1.355 (1.046–1.756) 0.022 1.410 (1.087–1.827) 0.010 1.406 (1.084–1.822) 0.010
PAD
 Nonrapid decliners 22246 300 Ref Ref Ref
 Rapid decliners 7416 130 1.301 (1.059–1.599) 0.010 1.306 (1.063–1.607) 0.011 1.287 (1.047–1.582) 0.017
Other types of CVD
 Nonrapid decliners 22246 746 Ref Ref Ref
 Rapid decliners 7416 287 1.157 (1.010–1.326) 0.036 1.177 (1.027–1.348) 0.019 1.170 (1.022–1.340) 0.024
CVD (Composite)
 Nonrapid decliners 22246 2210 Ref Ref Ref
 Rapid decliners 7416 868 1.190 (1.100–1.287) < 0.001 1.221 (1.1294–1.322) < 0.001 1.216 (1.124–1.315) < 0.001

Model 1: unadjusted; Model 2: adjusted for gender, education level, height, and BMI; Model 3: adjusted for gender, education level, height, BMI, smoking status, alcohol consumption frequency, hypertension, and diabetes. Composite endpoint includes CHD, arrhythmia, HF, PAD, endocarditis, stroke, and myocardial diseases

HR Hazard Ratio, CI Confidence Interval, FEV1 Forced expiratory volume in 1 s, CHD Coronary Heart Disease, HF Heart Failure, PAD Peripheral Arterial Disease, CVD Cardiovascular Disease